A fraction of polycythemia vera (PV) and essential thrombocythemia (ET) cases will, in time, undergo myelofibrotic transformation. In such cases, fibrosis may mask the diagnostic histologic features of the original underlying myeloproliferative neoplasm. Thus, confidently differentiating postfibrotic PV/ET from primary myelofibrosis (PMF) histologically may not be possible. It is controversial whether post-PV/ET myelofibrosis (MF) differs clinicopathologically from PMF, or whether these entities are biologically, clinically, and prognostically indistinguishable. To answer this question, we compared multiple candidate biological, morphologic, and prognostic parameters between 19 postfibrotic ET/PV individuals and 18 PMF individuals. The postfibrotic ET/PV and PMF cases did not differ with regard to clinical outcome, cytogenetic abnormalities, serum lactate dehydrogenase level, peripheral blast count, bone marrow morphology, or grade of reticulin fibrosis. Only JAK2 allele burden, which was higher in the postfibrotic PV/ET population (P = 0.011), differed between the 2 groups. Cardinal morphologic features of PMF (ie, marrow cellularity, intrasinusoidal hematopoiesis, osteosclerosis, etc.) were commonly observed in post-PV/ET MF marrow biopsies, and only a minority of post-PV/ET MF marrow biopsies the retained diagnostic features of the primary myeloproliferative neoplasm (panmyelosis in PV and megakaryocytic hyperplasia in ET). Our study indicates that PMF and post-PV/ET MF are clinically and biologically indistinguishable.
(ET), and primary myelofibrosis (PMF) are the 3 classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). 1 In the terminal stages (spent phase) of PV and ET, significant myelofibrosis (MF) may obscure the histologic features of the underlying primary MPN to the degree that individuals with post-PV/ET MF may have bone marrow morphologically indistinguishable from PMF. 2 The morphologic continuum of the fibrosing process and the inherently subjective nature in grading MF contribute to the diagnostic conundrum in differentiating between post-PV/ET MF and PMF. 3 In addition, it is unclear whether post-PV/ET MF is clinicopathologically distinct from PMF.
We attempt to address this difficult differential diagnosis. Multiple clinical, biological, prognostic, and bone marrow morphologic features (ie, degree of marrow fibrosis as determined by quantitative digital image analysis) were studied in well-characterized post-PV/ET and PMF individuals in an effort to identify parameters, which may aid in discriminating between these 2 entities.
METHODS

Patient Selection
A total of 103 cases of Philadelphia chromosomenegative MPNs with MF diagnosed at our institution between 1981 and 2013 were retrospectively reviewed using 2008 WHO criteria following Institutional Review Board approval. Of them, 66 cases were excluded because of nonavailability of high-quality diagnostic material, insufficient clinical follow-up, or lack of molecular studies. Eighteen cases of PMF and 19 cases of PV (n = 10) and ET (n = 9) that developed into post-PV/ET MF were identified.
The original diagnosis was confirmed in all 18 cases of PMF and 10 cases of PV using 2008 WHO criteria. Of the ET cases, original diagnostic material was not available in 2 cases. Prefibrotic MF cases were excluded on the basis of clinical findings and 2008 WHO criteria for relative cellular composition of marrow plus megakaryocyte morphology. 1, 4, 5 Post-PV/ET MF cases were defined as individuals with a confirmed diagnosis of PV/ET (again using 2008 WHO criteria) with documented progression to grade 2 and 3 bone marrow fibrosis (on a 0 to 3 scale) identified by reticulin and trichrome staining, as per the criteria set by the International Working Group for Myelofibrosis Research and Treatment. 6, 7 Morphologic Review and Assessment Morphologic review of the peripheral blood smears, bone marrow aspirates, and core biopsies were carried out for each case. Two hematopathologists (M.S. and N.S.), blinded to the original diagnosis, assessed and quantified key histomorphologic features (ie, megakaryocyte clustering, size, and nuclear lobulation, marrow cellularity and composition, intrasinusoidal hematopoiesis). Histomorphologic criteria of megakaryocytes including size, nuclear features, and clustering were considered present if noted in at least 10% of the cells.
Digital image analysis was used to objectively grade and quantitate the degree of MF in the reticulin-stained bone marrow core biopsies. In addition, traditional subjective grading of fibrosis was performed in the standard manner aided by reticulin. 6 The slides were digitally scanned with ScanScopeXT system and the reticulin fibrosis was quantified using a color deconvolution algorithm provided in ScanScope software (Aperio Technologies Inc., Vista, CA), as previously described. 3 The fibrosis quantification score was defined as the proportion of total hematopoietic area (excluding trabeculae) occupied by reticulin fibers. The objective quantification of fibrosis using digital image analysis was highly correlated with the subjective fibrosis score (Spearman correlation, R = 0.79; data not shown).
Molecular Analysis
Molecular studies included JAK2 V617F mutant allele quantitation and MPL (W515K/L) mutational status. A quantitative real-time polymerase chain reaction-based allelic discrimination assay was used to determine the percentage of granulocyte mutant alleles for JAK2 V617F, as previously described. 8 
Flow Cytometric Analysis
Flow cytometric studies were conducted on peripheral blood. Parameters measured included peripheral CD34 + blast percentages of total leukocytes, coexpression frequency of adhesion molecule CXCR4 (CD184), and blast characterization, using CD38, CD45RA, and IL-3 Ra (CD123).
On the basis of phenotype, circulating myeloid progenitors were categorized as common myeloid progenitors (CMP: CD34 + /CD38 + , CD45RA À , CD123 + ), gran-ulocyte/macrophage progenitors (GMP: CD34 + /CD38 + , CD45RA + , CD123 + ), or megakaryocyte/erythrocyte progenitors (MEP: CD34 + /CD38 + , CD45RA À , CD123 À ). 9 CMP or their downstream progeny subpopulations were considered significant if they represented Z30% of the CD34 + /CD38 + cells.
Cytogenetic Analysis
Conventional cytogenetic studies were conducted in all post-PV/ET MF and PMF individuals.
Clinical Outcome
Clinical features, including serum lactate dehydrogenase (LDH) levels and event-free survival characteristics (ie, development of vascular thrombosis, death, transformation to acute leukemia, or similar adverse events), in the post-PV/ET MF and the PMF groups were assessed.
Statistical Analysis
Generalized linear models were used when comparing continuous variables. Fisher exact tests were used for comparing categorical variables. Statistical analyses were performed using the SAS software, Version 9.1 of the SAS system (SAS Institute Inc., Cary, NC). Results were considered statistically significant if P < 0.05. The fibrotic transformation of both PV and ET was grouped together as post-PV/ET MF group for comparison with the PMF group. Combined PV/ET MF were also compared with PMF JAK2 mutated and PMF JAK2 nonmutated cohorts.
RESULTS
Objective assessment of the grade of MF using image analysis techniques showed no difference between PMF and fibrotic transformation of PV or ET ( Fig. 1 ). Traditional subjective grading of the reticulin stain gave Informative cytogenetic studies were available in 8 post-PV/ET MF and 13 PMF individuals. The frequency and complexity of cytogenetic abnormalities were subjectively similar between the 2 groups ( Table 1 ). The post-PV/ET MF cohort showed a normal karyotype in 5 of the 8 specimens. Noncomplex cytogenetic abnormalities nonspecific for MPNs were detected in 2 of the 8 specimens (a 13q deletion and a 1q addition). The single PV/ ET MF specimen with complex cytogenetic changes included nonspecific abnormalities commonly reported in MPNs and other hematopoietic disorders (monosomy 7, a 20q deletion, and a 5q deletion). The PMF cohort showed a normal karyotype in 9 of the 13 specimens, 2 specimens each with simple nonspecific chromosomal abnormalities, and 2 specimens with complex cytogenetic abnormalities. One of the PMF specimens with complex cytogenetic changes included the recurrent +8, +9, gain of 1q, and loss of 7 abnormalities commonly reported in MPNs and other myeloid disorders.
Flow cytometric studies for circulating myeloid progenitors were available for 13 post-PV/ET MF individuals and 18 PMF individuals. When compared, the peripheral blast count and the relative contribution of Table 2 ). The adhesion molecule CXCR4 (CD184) expression in circulating blasts was similar between the 2 groups. In our cohort, PV and ET patients developed MF at a median of 185 (range, 31 to 359) and 130 (range, 60 to 233) months, respectively ( Table 2) . We found LDH levels in the post-PV/ET MF group to be equally high (median, 853; range, 249 to 1709) as the PMF group (median, 935; range, 63 to 1741), with no statistically significant difference between the 2 groups ( Table 2) .
Follow-up data (timed from progression to MF) in post-PV MF ranged from 1 to 96 (median = 31) months, and for post-ET MF patients ranged from 1 to 72 (median = 14) months. PMF patients had follow-up data ranging over a period of 3 to 252 (median = 27) months from the time of diagnosis ( Table 2 ). Occurrence of clinical events, in particular, transformations to acute leukemia, death, vascular thrombosis, and other similar complications, was considered. In the post-PV MF group, 1 patient developed AML after 71 months of progression to MF, and another patient died because of an unrelated reason. In the post-ET MF cohort, 1 patient developed AML at the onset of MF, and another had splenic thrombosis; 3 patients in this group had expired (because of unrelated reasons) at the time of last follow-up. In the PMF group, 1 patient expired following transformation to acute leukemia, and another died because of unrelated reasons. Use of statistical methods in evaluating eventfree survival was limited owing to the small sample size and infrequency of events.
The MPL W515K/L mutation was detected in a single post-PV/ET MF individual and was not detected in any of the PMF individuals.
The only parameter to show a statistical difference between the 2 groups was JAK2 V617 mutation allelic burden ( Table 2) , P = 0.011. This was significantly higher in the post-PV/ET MF patients, when compared with the PMF patients. The subgroup analysis separately comparing post-PV/ET MF individuals with JAK2-mutated PMF and JAK2-nonmutated PMF individuals revealed no statistical differences for any of the above parameters.
DISCUSSION
MPN are a heterogenous group of clonal disorders affecting 1 or several myeloid cell lineages. Accurate categorization of MPN requires a combination of clinical, histomorphologic, and molecular data, and bone marrow histology is essential. 5 It is not uncommon for MPNs, such as ET or PV, to develop fibrosis in the terminal stages, rendering them difficult to distinguish from PMF in the absence of clinical information or sequential biopsies. 2 Previous studies have not addressed whether post-PV/ET MF and PMF differ in biological, clinical, or prognostic features. Post-PV/ET fibrosis and PMF share overlapping features that, in some cases, makes distinguishing between these entities difficult to impossible without appropriate clinical history or sequential bone marrow studies. Specifically, neither the score of MF using quantitative image analysis, bone marrow histology, nor megakaryocyte morphology/histotopography were sufficiently different in our study to reliably distinguish between PMF and post-PV/ET MF.
The only biological parameter that differed significantly between the 2 study groups was JAK2 V617 mutation allele burden (P = 0.011), which was higher in the post-PV/ET MF individuals compared with PMF individuals. This is consistent with previous studies reporting a direct relationship between high JAK2 mutant allele burden and the risk for developing MF in PV. 10, 11 Approximately 5% of PV and about 50% of ET and PMF patients are negative for JAK2 V617F mutation. Mutations of the thrombopoietin receptor gene (MPL) at codon 515 (W515K/L) have been reported in up to 10% of JAK2 V617F mutation-negative ET and PMF patients. 12 In our series, only 1 post-PV/ET MF patient had an MPL mutation.
Increased serum LDH levels are part of the WHO minor criteria for the diagnosis of PMF; however, in our experience, LDH levels in the post-PV/ET MF individuals are equally high.
In PMF, increased CD34 + progenitors are often increased in peripheral blood possibly because of reduced CXCR4 adhesion protein expression. 13 ET and PV (without MF) are not associated with a significant increase in circulating CD34 + progenitors. 14 We found that CD34 + percentages were increased in all 3 groups, but the coexpression of the adhesion molecule CXCR4 (CD184) on circulating blasts and maturational patterns in post-PV/ET MF and PMF groups showed no significant differences.
CONCLUSIONS
Our findings indicate that, with the exception of a higher JAK2 mutant allelic burden observed in the post-PV/ET MF group, there are otherwise no morphologic, phenotypic, or prognostic differences between patients with post-PV/ET MF or PMF. Despite the small sample size, our study indicates that these 2 groups are prognostically similar and biologically indistinguishable. Until further validation in larger studies, our findings suggest that these entities be considered as equivalent for diagnostic and management purposes. 
